๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Evaluation of systemic chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin for advanced bladder cancer

โœ Scribed by Toshihiko Kotake; Hideyuki Akaza; Shigoe Isaka; Susumu Kagawa; Kenkichi Koiso; Toyohei Machida; Akio Maru; Yosuke Matsumura; Ikuo Miyagawa; Tadao Niijima; Koji Obata; Yasuo Ohashi; Hiroshi Ohe; Yoshitada Ohi; Eigoro Okajima; Yasunosuke Sakata; Jun Shimazaki; Kazuya Tashiro; Masaki Togashi; Toyofumi Ueda; Takeshi Uyama; Kazuyuki Yoshikawa

Publisher
Springer
Year
1992
Tongue
English
Weight
469 KB
Volume
30
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Carboplatin, methotrexate, and vinblasti
Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy
โœ J. Bellmunt; J. Albanell; O. S. Gallego; A. Ribas; P. Vicente; J. Carulla; J. De ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 622 KB

Background. A Phase I1 trial with a new regimen of methotrexate, carboplatin, and vinblastine (M-CAVI) was conducted for patients with bladder cancer who could not receive cisplatin-based chemotherapy. Methods. Treatment consisted of methotrexate (30 mg/m2) on days 1,15, and 22; carboplatin (300 mg

Chemotherapy for head and neck cancer. C
Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate
โœ Stephen D. Williams; Enrique Velez-Garcia; Issac Essessee; Gary Ratkin; Robert B ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 575 KB

One hundred ninety-one patients with recurrent or metastatic squamous cell carcinoma of head and neck origin were allocated at random to chemotherapy with conventional-dose weekly intravenous methotrexate or the combination of cisplatin, vinblastine, and bleomycin. Methotrexate induced responses in